Prostate-specific membrane antigen (PSMA) is an ∼100 kDa transmembrane glycoprotein that is abundantly and preferentially expressed in prostate cancer, including recurrent and hormone-refractory cases. rsPSMA Vaccine is a subunit vaccine... The vaccine comprises purified rsPSMA protein formulated with Alhydrogel® adjuvant.
- Mechanism
- Curator reviewed
rsPSMA vaccine with Alhydrogel demonstrated safety and tolerability in addition to the induction of high-titer PSMA-specific antibodies (Abs) by ELISA with specificity directed to cell-surface, native PSMA as indicated by FACS analysis using cells expressing PSMA.
Like native, cell-surface PSMA, the rsPSMA protein was discovered to form a noncovalent dimer, and only the dimeric form of rsPSMA was enzymatically active and capable of inducing high levels of antibodies that cross-react with PSMA-expressing tumor cells. The findings provide important proof-of-concept for our rsPSMA vaccine
- Primary indication
- Investigated for use/treatment in prostate cancer.Curator reviewed
- Also known as
- Recombinant soluble prostate-specific membrane antigen (rsPSMA) vaccine · rsPSMA
What you can answer from here — as of April 02, 2025
Which companies are running trials of rsPSMA Vaccine, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account